Aptamers with Self-Loading Drug Payload and pH-Controlled Drug Release for Targeted Chemotherapy
Doxorubicin (DOX) is a common anti-tumor drug that binds to DNA or RNA via non-covalent intercalation between G-C sequences. As a therapeutic agent, DOX has been used to form aptamer–drug conjugates for targeted cancer therapy in vitro and in vivo. To improve the therapeutic potential of aptamer–DOX...
Main Authors: | Zihua Zeng, Jianjun Qi, Quanyuan Wan, Youli Zu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/8/1221 |
Similar Items
-
An Aptamer for Broad Cancer Targeting and Therapy
by: Bethany Powell Gray, et al.
Published: (2020-10-01) -
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
by: Sara Ponziani, et al.
Published: (2020-07-01) -
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems
by: Feng Jiang, et al.
Published: (2015-10-01) -
Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
by: Prabir Kumar Kulabhusan, et al.
Published: (2020-07-01) -
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
by: Dou XQ, et al.
Published: (2018-02-01)